Gynecol Oncol 2021 Aug 23. Epub 2021 Aug 23.
Nagourney Cancer Institute, 750 East 29th Street, 90806 Long Beach, CA, USA; Metabolomycs, Inc., 750 East 29th Street, 90806 Long Beach, CA, USA; Memorial Medical Center of Long Beach, Todd Cancer Institute, 2810 Long Beach Blvd, Long Beach 90806, CA, USA; Department of Obstetrics and Gynecology, University of California Irvine (UCI) School of Medicine, 101 The City Drive South, Orange 92868, CA, USA.
Objective: Platinum resistance, defined as the lack of response or relapse within six months of platinum-based chemotherapy, is an important determinant of survival in gynecologic cancer. We used quantitative Mass Spectrometry to identify metabolic signatures that predict platinum resistance in patients receiving chemotherapy for gynecologic cancers.
Methods: In this study 47 patients with adenocarcinoma of the ovary or uterus who were candidates for carboplatin plus paclitaxel submitted blood for quantitation of metabolites and surgical specimens for the isolation 3-dimensional organoids used to measure individual patient platinum resistance, ex vivo. Read More